Important Safety Information
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
GET READY FOR IMPROVEMENT
Xiidra is the only eye drop approved to treat both the signs and symptoms of Dry Eye Disease.2-4 Xiidra improved patient-reported symptoms of eye dryness and signs of inferior corneal staining in clinical trials.2 Think about Xiidra for symptomatic Dry Eye patients.2
Four randomized, double-masked, 12-week trials evaluated the efficacy and safety of Xiidra versus vehicle as assessed by improvement in the signs (measured by Inferior Corneal Staining Score) and symptoms (measured by Eye Dryness Score) of Dry Eye Disease (N=2133).2
